ESHAP
ESHAP is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory lymphomas and Hodgkin lymphoma. In combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R.[1]
R-ESHAP consists of:
- Rituximab, an anti-CD20-directed monoclonal antibody that kills both normal and malignant B-lymphocytes
- Etoposide, an epipodophyllotoxin topoisomerase inhibitor
- Solu-Medrol - Methylprednisolone, which is a glucocorticoid that can lyse lymphocytes
- High-dose Ara-C - cytarabine
- Platinol - Cisplatin, a platinum-based antineoplastic agent, also an alkylating antineoplastic agent.
Dosing regimen
| Drug | Dose | Mode | Days |
|---|---|---|---|
| Rituximab | 375 mg/m2 | IV infusion | Day 0 |
| Etoposide | 40 mg/m2 | IV infusion over 1 hr | Days 1-4 |
| Solu-Medrol - Methylprednisolone | 500 mg | IV bolus over 15 min | Days 1-5 |
| High-dose Ara-C — cytarabine | 2000 mg/m2 | IV infusion over 2 hrs | Day 5 |
| Platinol (cisplatin) | 25 mg/m2 | IV continuous infusion over 24 hrs | Days 1-4 |
References
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.